|
|
Volumn 61, Issue 2, 2011, Pages 65-66
|
|
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DASATINIB;
IMATINIB;
INTERFERON;
NILOTINIB;
ANTINEOPLASTIC AGENT;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
CHRONIC MYELOID LEUKEMIA;
CLINICAL PROTOCOL;
DRUG RESPONSE;
DRUG WITHDRAWAL;
HUMAN;
LEUKEMIA RELAPSE;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
REVIEW;
RISK ASSESSMENT;
SURVIVAL RATE;
SURVIVAL TIME;
TREATMENT DURATION;
ARTICLE;
FEMALE;
MALE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
ANTINEOPLASTIC AGENTS;
FEMALE;
HUMANS;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
MALE;
PIPERAZINES;
PYRIMIDINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
|
|
EID: 79955012754
PISSN: 00079235
EISSN: 15424863
Source Type: Journal
DOI: 10.3322/caac.20110 Document Type: Review |
|
Times cited : (4)
|
|
References (0)
|